Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology.


Journal

Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558

Informations de publication

Date de publication:
01 2021
Historique:
received: 13 09 2019
revised: 28 01 2020
accepted: 02 04 2020
pubmed: 27 4 2020
medline: 4 9 2021
entrez: 27 4 2020
Statut: ppublish

Résumé

Systemic mastocytosis (SM) is a hematologic disease with a wide range of clinical courses ranging from an indolent condition with normal life expectancy to exceedingly aggressive disorder with a poor prognosis. The symptoms and signs of SM result from the release of mast cell mediators with heterogeneous functions, and/or organ damage from neoplastic mast cell infiltration, or both. Diagnostic criteria for SM are well-defined by the World Health Organization (WHO). However, the diagnosis of SM can be difficult when especially it is not in the differential diagnosis. Routinely used radiologic techniques (e.g., X-ray, ultrasound, CT scans can show findings such as lytic-, sclerotic- or mixed-bone lesions, splenomegaly, hepatomegaly, retroperitoneal or periportal mesenteric lymphadenopathy, and omental thickening). It is essential to emphasize that the constellation of these radiologic findings should strongly concern of SM, especially in patients who also have a skin rash, allergic reactions, gastrointestinal tract symptoms (lasting, intermittent nausea, diarrhea), paroxysmal tachycardias, unexplained weight loss, persistent bone pain, cytopenias, liver dysfunction, eosinophilia. These findings, even coincidentally noted, will likely lead to a tissue biopsy, which reveals diagnosis (as we discussed and illustrated some tissue biopsies here). Moreover, the role of MRI and new techniques such as [18-fluorodeoxyglucose positron emission computed tomography, fibroscan] in the diagnosis of SM have been discussed. Furthermore, we reviewed the use of radiologic methods to evaluate treatment response and prognostication of SM..

Identifiants

pubmed: 32334853
pii: S0268-960X(20)30043-6
doi: 10.1016/j.blre.2020.100693
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100693

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Kerem Ozturk (K)

Department of Radiology, University of Minnesota Medical Center, Minneapolis, MN, USA.

Zuzan Cayci (Z)

Department of Radiology, University of Minnesota Medical Center, Minneapolis, MN, USA.

Jason Gotlib (J)

Division of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, CA, USA.

Cem Akin (C)

Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA.

Tracy I George (TI)

Department of Pathology, University of Utah, Salt Lake City, UT, USA.

Celalettin Ustun (C)

Division of Hematology, Oncology and Cellular Therapy, Department of Medicine, Rush University, Chicago, IL, USA. Electronic address: celalettin_ustun@rush.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH